title: DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
abstract: The concept of leukaemic stem cells (LSCs) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients. Some of the newly discovered LSC markers seem to be expressed in a disease-specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia (CML) appears to be CD26, also known as dipeptidylpeptidase IV. Expression of CD26 is largely restricted to CD34(+) /CD38(-) LSCs in BCR/ABL1(+) CML, but is not found on LSCs in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML, BCR/ABL1p210 + acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD26 usually is not expressed on normal bone marrow (BM) stem cells. Functionally, CD26 is a cytokine-targeting surface enzyme that may facilitate the mobilization of LSCs from the BM niche. In this article, we review our current knowledge about the biology and function of CD26 on CML LSCs and discuss the diagnostic potential of this new LSC marker in clinical haematology.
authors.affiliation: Division of Haematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Irina
authors.initials: I
authors.lastname: Sadovnik
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Ráčil
authors.forename: Harald
authors.initials: H
authors.lastname: Herrmann
authors.forename: Katharina
authors.initials: K
authors.lastname: Blatt
authors.forename: Sabine
authors.initials: S
authors.lastname: Cerny-Reiterer
authors.forename: Gregor
authors.initials: G
authors.lastname: Eisenwort
authors.forename: Thomas
authors.initials: T
authors.lastname: Lion
authors.forename: Tessa
authors.initials: T
authors.lastname: Holyoake
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism* / Q000502:physiology; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism* / Q000502:physiology; D055088:Early Detection of Cancer; D005544:Forecasting; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D018819:Dipeptidyl Peptidase 4
keywords: Diagnostics; leukaemia; leukaemic stem cells; phenotyping; stem cell